Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

What’s at stake in Australia’s biggest pharma patent appeal in years?
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.   1 July 2026
Vinson & Elkins grows West Coast patent and trade secrets bench
Careers
Vinson & Elkins grows West Coast patent and trade secrets bench
A first-chair trial lawyer with two decades in high-stakes patent and trade secret disputes brings experience across medical devices, biologics, and pharmaceuticals, alongside a broader technology-focused practice.   1 July 2026
Will Mounjaro and Zepbound get their first US generic rival?
Pharma
Will Mounjaro and Zepbound get their first US generic rival?
Sandoz has filed FDA applications for generic versions of Eli Lilly’s blockbuster drugs, marking an early step towards potential competition in the fast-growing GLP-1 market.   30 June 2026
Careers
King & Spalding continues hiring spree from pre-merged Winston
The latest additions bring experience representing technology and medical device companies in complex patent and commercial disputes, with the firm extending its run of bringing in partners from Winston & Strawn before its merger.   30 June 2026
Regulation & Industry
Ashurst Perkins Coie opens its doors following landmark merger
The newly combined transatlantic firm brings together more than 950 partners across 20 countries, uniting leading patent, trade secrets, life sciences, and tech practices.   29 June 2026
Biotech
Pfizer’s US Paxlovid patent fight turns on a single error
The Federal Circuit has brought Paxlovid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences.   25 June 2026
Careers
Cooley Asia transactions duo make rival firm move
The pair bring a strong track record advising life sciences companies on licensing, collaboration and commercialisation agreements, with a particular focus on cross-border biotech transactions.   23 June 2026
Regulation & Industry
Insilico lands potential $2.5bn AI biotech partnership
The partnership, announced at BIO 2026, marks the largest Asia-Pacific partnership by potential value that the AI-driven drug discovery company has secured to date.   22 June 2026
Asia
‘Blatant imitation’: Indian court blocks copycat pharma branding
The court granted Blue Cross Laboratories a permanent injunction after finding that a rival product’s mark and packaging closely mirrored its own.   22 June 2026
Europe
UPC hands Occlutech second win against Chinese medtech company in a month
The court overturns a decision granting the German-based company provisional measures and ordering a Chinese medtech rival to stop selling its device in four European countries.   19 June 2026

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.